FAKTION: Updated and Expanded Analysis of Fulvestrant + Capivasertib or Placebo After Aromatase Inhibitor Therapy in ER+/HER2- Advanced Breast Cancer

June 3-7, 2022; Chicago, Illinois
Results from the randomized phase II FAKTION trial showed that the addition of capivasertib to fulvestrant prolongs survival in ER+/HER2- advanced breast cancer and suggest that capivasertib primarily benefits patients with PI3K/AKT/PTEN pathway alterations.
Format: Microsoft PowerPoint (.ppt)
File Size: 189 KB
Released: June 9, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Seattle Genetics

Related Content

Expert faculty provide insights into the role and utility of Ki-67 testing in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

person default Sunil Badve, MD, FRCPath Laura M. Spring, MD Released: September 26, 2022

Dr Denise Yardley discusses key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 22, 2022 Expired: September 21, 2023

Downloadable slides from Dr Denise Yardley on key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Released: September 22, 2022

Slideset from Dr Denise Yardley on immunotherapy in early TNBC, from Clinical Care Options (CCO)

Denise A. Yardley, MD
Program Director
Released: September 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings